Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment

Clinical Cancer Research

Volumn 4, Issue 4, 1998, Pages 1047-1054

  Fan, Saijun ^a,c   Cherney, Barry ^d   Reinhold, William ^c   Rucker, Kimberly ^c   O'Connor, Patrick M ^b,c  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b AGOURON PHARMACEUTICALS INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA; ETOPOSIDE; PACLITAXEL; PROTEIN P53; VINCRISTINE;

APOPTOSIS; ARTICLE; CELL IMMORTALIZATION; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DRUG SENSITIVITY; GAMMA IRRADIATION; GENE DISRUPTION; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WART VIRUS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, P53; HUMANS; LYMPHOMA; MUTATION; PACLITAXEL; RADIATION, IONIZING; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 0031953822     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Zambetti, G. P., and Levine, A. J. A comparison of the biological activities of wild-type and mutant p53. FASEB J., 7: 855-865, 1993.
2. Hartwell, L., and Kastan, M. B. Cell cycle control and cancer. Science (Washington DC), 266: 1821-1828, 1994.
3. 2 phase checkpoints. Cancer Surv., 29: 151-182, 1997.
4. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-52, 1991.
5. Levine, A., Momand, J., and Finlay, C. A. The p53 tumour suppressor gene. Nature (Lond.), 351: 453-456, 1991.
6. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 847-849, 1993.
7. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 849-852, 1993.
8. Lowe, S. W., Ruley, H. E., Jacks, T., and Houseman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
9. O'Connor, P. M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., and Kohn, K. W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776-4780, 1993.
10. McIlwrath, A. J., Vasey, P. A., Poss, G. M., and Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res., 54: 3718-3722, 1994.
11. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J., Jr., Magrath, I., Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA-damaging agents. Cancer Res., 54: 5824-5830, 1994.
12. Radford, I. R., Murphy, J. M., Radley, J. M., and Ellis, S. L. Radiation response of mouse lymphoid and myeloid cell lines. Part II. Apoptotic death is shown by all lines examined. Int. J. Radiat. Biol., 65: 217-227, 1994.
13. Vasey, P. A., Jones, N. A., Jenkins, S., Dive, C., and Brown, R. Cisplatin, camptothecin, and Taxol sensitivities of cells with p53-associated multidrug resistance. Mol. Pharmacol., 50: 1536-1540, 1996.
14. O'Connor, P. M., Jackman, J., Bae, I., Myers, T., Fan, S., Scudiero, D., Monks, A., Sausville, E., Weinstein, J., Friend, S., Fornace, A. J., Jr., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
15. Brachman, D. G., Beckett, M., Graves, D., Haraf, D., Vokes, E., and Weichselbaum, R. R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res., 53: 3667-3669, 1993.
16. Slichenmyer, W. J., Nelson, W. G., Slebos, R. J., and Kastan, M. B. Loss of a p53-associated G, checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53: 4164-4168, 1993.
17. Fan, S., Chang, J. K., Smith, M. L., Duba, D., Fornace, A. J., Jr., and O'Connor, P. M. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene, 14: 2127-2136, 1997.
18. Fan, S., Smith, M. L., Rivet, D. J., Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., Jr., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
19. Smith, M. L., Chen, I. T., Zhan, Q., O'Connor, P. M., and Fornace, A. J., Jr. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene, 10: 1053-1059, 1995.
20. Hawkins, D. S., Demers, G. W., and Galloway, D. A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56: 892-898, 1996.
21. Horwitz, S. B. Taxol (paclitaxel): mechanisms of action. Annals of Oncol., 5(Suppl. 6): S3-S6, 1994.
22. Horwitz, S. B., Cohen, D., Rao, S., Ringel, I., Shen, H. J., and Yang, C. P. H. Taxol: mechanisms of action and resistance. J. Natl. Cancer Inst., 15: 55-61, 1993.
23. cip1/waf1 proteins following γ-irradiation of human lymphoma cells. Cancer Res., 55: 2387-2393, 1995.
24. Zhan, Q., Fan, S., Bae, I., Guillouf, C., Liebermann, D. A., O'Connor, P. M., and Fornace, A. J., Jr. Abrogation of p53 function affects gadd gene responses to DNA base-damaging agents and starvation. Oncogene, 9: 3743-3751, 1994.
25. L depends on normal p53 function. Oncogene, 13: 2287-2293, 1996.
26. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
27. Werness, B. A., Levine, A. J., and Howley, P. M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science (Washington DC), 248: 76-79, 1990.
28. Crook, T., Wrede, D., and Vousden, K. H. p53 point mutation in HPV-negative human cervical carcinoma cell lines. Oncogene, 6: 873-875, 1991.
29. Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Jr., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., Buolamwini, J. K., van Osdal, W. W., Monks, A. P., Scudiero, D. A., Sausville, E. A., Zaharevitz, D. W., Bunow, B., Johnson, G. S., Wittes, R. E., and Paull, K. D. An information-intensive approach to the molecular pharmacology of cancer. Science (Washington DC), 275: 343-349, 1997.
30. Debernardis, D., Sire, E. G., Feudis, P., Vikhanskaya, F., Valenti, M., Russo, P., Parodi, S., D'Incalci, M., and Broggini, M. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res., 57: 870-874, 1997.
31. Wu, G. S., and El-Deiry, W. S. p53 and chemosensitivity. Nat. Med., 2: 255-256, 1996.
32. Safran, H., King, T., Choy, H., Gollerki, A., Kwakwa, H., Lopez, F., Cole, B., Myers, J., Tarpey, J., and Rosmarin, A. p53 mutations do not predict response to paclitaxel/radiation for non-small cell lung carcinoma. Cancer (Phila.), 78: 1203-1210, 1996.